Northwell Health NCORP

诺斯韦尔健康 NCORP

基本信息

批准号：
10703683
负责人：
VINCENT P VINCIGUERRA
金额：
$ 11.79万
依托单位：
FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-08-07 至 2025-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10703683
关键词：
2019-nCoV Adherence Affect Aftercare Age Antibodies Attention Autoimmune Diseases COVID-19 COVID-19 patient Cancer Burden Cancer Control Cancer Patient Caring Catchment Area China Clinical Trials Collaborations Communicable Diseases Communities Community Healthcare Community Physician Community Practice Computerized Medical Record Continuity of Patient Care Country County Data Data Analyses Diagnosis Diagnostic Economics Education Evidence based practice Goals Health Health Personnel Health Priorities Health Services Health system Healthcare Healthcare Systems Heterogeneity Immunity Individual Inflammatory Bowel Diseases Institutes Institution Knowledge Laboratories Lead Length Malignant Neoplasms Measures Medicine Meta-Analysis Minority Recruitment Mission Monitor Morbidity - disease rate Needs Assessment New York Operative Surgical Procedures Outcome Patient Recruitments Patient-Focused Outcomes Patients Physicians Population Predisposition Prevention Primary Health Care Prospective cohort study Quality of life Research Rheumatoid Arthritis Risk Factors Science Serology Services Site System Systemic Lupus Erythematosus Techniques Technology Testing Time Underserved Population Variant Virus Wellness Program Woman Work base cancer care cancer clinical trial cancer prevention cancer therapy care delivery clinical practice clinical risk cohort demographics effective therapy health equity immunological status improved knowledge translation medical specialties mortality multidisciplinary outreach palliation pandemic disease prospective screening social social health determinants transmission process vaccination outcome vaccine access vaccine development vaccine effectiveness

项目摘要

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2). The global pandemic that started in China in December 2019 has seen both development of vaccines in December 2020, and emergence of successive variants of the virus which alter the efficacy of the available vaccines. At this point in time, the correlates of susceptibility have not been adequately characterized, particularly in patients with compromised immunologic status. Reducing SARS-CoV-2 transmission, morbidity and mortality at both the individual and population level will require better understanding of immunity to this virus. The Serological Sciences Network (SeroNet) was established in 2020 as a consortium of institutions to explore the diagnostic and investigative laboratory science of immunity to SARS-CoV-2, and to prospectively track cohort populations for outcomes, with especial attention to post-vaccination outcomes in susceptible individuals. For this study, 11 of the SeroNet institutions have come together for a "Pooling Project" consisting of conducting real-world data (RWD) analysis using electronic medical record (EMR) data (4 institutions); conducting meta-analyses of the ongoing prospective cohort studies (8 institutions); and investigating heterogeneity in vaccine effectiveness according to age, social determinants of health (SDoH), common clinical risk factors, and laboratory-based correlates of immunohematologic function (4 institutions). This Feinstein (FIMR)/Northwell application is for the purposes of: (a) serving as lead institution for the RWD analyses of patients with autoimmune conditions (systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease); (b) serving as co-lead institution for the RWD analyses of patients with cancer; and (c) serving as co-lead institution for the meta-analysis of prospective cohort studies of patients with systemic lupus erythematosus. Northwell health is a nonprofit integrated healthcare network that is New York State's largest healthcare provider, and by patient volumes over the length of the pandemic, has been one of the top healthcare systems in the country for care of COVID-19 patients. Thanks to its in-system integrated laboratory network (Northwell Health Laboratories), extensive SARS-CoV-2 RWD is available, both for diagnostic (PCR) and serologic (Antibody) testing. This 2-year project will pursue both analysis of extant RWD, and monitoring of the relevant cohort populations over the course of the 2-year study

2019年冠状病毒病（COVID-19）是由严重急性呼吸窘迫综合征2（SARS-COV-2）引起的一种传染病。 2019年12月在中国启动的全球大流行在2020年12月既有疫苗的开发，又出现了这种病毒的连续变体，这改变了可用疫苗的功效。此时，尚未充分表征易感性的相关性，尤其是在具有损害的免疫学状态的患者中。降低个人和人口水平的SARS-COV-2传播，发病率和死亡率都将需要更好地理解该病毒的免疫力。血清学科学网络（Seronet）成立于2020年，是一个机构的财团，探索了对SARS-COV-2的免疫力的诊断和调查实验室科学，并前瞻性地跟踪了群体的结果，并特别关注后接种后的竞争后观察结果在易感人士中。在这项研究中，11个Seronet机构已经聚集在一起，用于“合并项目”，其中包括使用电子医疗记录（EMR）数据（4个机构）进行现实世界数据（RWD）分析；进行正在进行的前瞻性队列研究的荟萃分析（8个机构）；并根据年龄，卫生社会决定因素（SDOH），常见的临床风险因素和基于实验室的免疫血液学功能（4个机构）的相关性研究疫苗有效性的异质性。这项Feinstein（FIMR）/Northwell的应用是出于以下目的：（a）作为自身免疫性疾病（全身性红斑狼疮，类风湿关节炎，炎性肠病）的RWD分析的铅机构；（b）作为癌症患者RWD分析的共同领导机构；（c）作为全身性红斑狼疮患者的前瞻性队列研究荟萃分析的共同研究机构。 Northwell Health是一个非营利性综合医疗网络，是纽约州最大的医疗保健提供者，并且按照大流行期限的患者量，一直是该国护理COVID-19患者的顶级医疗系统之一。多亏了其系统内集成实验室网络（Northwell Health Laboratories），可用于诊断（PCR）和血清学（抗体）测试，可提供广泛的SARS-COV-2 RWD。这个为期两年的项目将既可以进行现有RWD的分析，又要监视相关队列人群在2年的研究过程中